Form 8-K - Current report:
SEC Accession No. 0001193125-25-115089
Filing Date
2025-05-07
Accepted
2025-05-07 17:25:03
Documents
16
Period of Report
2025-05-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d51125d8k.htm   iXBRL 8-K 30004
2 EX-1.1 d51125dex11.htm EX-1.1 191852
3 EX-5.1 d51125dex51.htm EX-5.1 4913
7 GRAPHIC g51125g0507120130305.jpg GRAPHIC 7175
  Complete submission text file 0001193125-25-115089.txt   417354

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA cycn-20250507.xsd EX-101.SCH 2855
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE cycn-20250507_lab.xml EX-101.LAB 17993
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cycn-20250507_pre.xml EX-101.PRE 11264
19 EXTRACTED XBRL INSTANCE DOCUMENT d51125d8k_htm.xml XML 3663
Mailing Address 301 BINNEY STREET CAMBRIDGE MA 02142
Business Address 301 BINNEY STREET CAMBRIDGE MA 02142 617-621-7722
Cyclerion Therapeutics, Inc. (Filer) CIK: 0001755237 (see all company filings)

EIN.: 831895370 | State of Incorp.: MA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38787 | Film No.: 25922845
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)